PET

EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan

Retrieved on: 
Wednesday, March 13, 2024

Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.

Key Points: 
  • Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.
  • (Japan).
  • For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert & Ziegler’s proprietary Ge-68/Ga-68 generator GalliaPharm® as the single source for Ga-68.
  • “We are happy to extend our radioisotope supply business in Japan by contributing our GalliaPharm® to this important clinical research project,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler AG.

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Retrieved on: 
Wednesday, March 13, 2024

Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.

Key Points: 
  • Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.
  • Key terms of the agreement between Heidelberg Pharma and HCRx:
    Following the receipt by HCRx of a maximum cumulative amount, royalty payments will revert to Heidelberg Pharma and HCRx will receive a low single digit royalty tail percentage thereafter
    Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, commented: “We are delighted to partner with HealthCare Royalty.
  • This agreement will provide us with a non-dilutive financing based on expected royalty payments from the worldwide sales of ZircaixTM.
  • Heidelberg Pharma will hold a conference call on 25 March 2024 with the publication of the Annual Report.

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

Retrieved on: 
Thursday, March 7, 2024

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.

Key Points: 
  • PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy.
  • Today’s announcement follows the decision in July 2023 by the European Commission granting marketing authorization for PYLCLARI® in the European Union.
  • On 3rd February 2024 The Italian Medicines Agency (Agenzia Italiana del Farmaco) published the decision for PYLCLARI® in Italy.
  • The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018.

Sabert Serves Up Excitement with the new Catering Pop-Top Family

Retrieved on: 
Tuesday, March 5, 2024

SAYREVILLE, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Sabert Corporation, a leading global manufacturer of innovative and sustainable food packaging solutions, announces the launch of its new Catering Pop-Top family.

Key Points: 
  • SAYREVILLE, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Sabert Corporation, a leading global manufacturer of innovative and sustainable food packaging solutions, announces the launch of its new Catering Pop-Top family.
  • A game-changer for foodservice operators, this distinctive catering bowl line offers unmatched functionality and convenience for any catering occasion, from workplace meetings to large-scale events.
  • The Catering Pop-Top features a unique hinged lid that folds back, clicks into place and can be rotated 90 degrees to display one or both sides of the base.
  • Available in one or two-compartment bases, the Catering Pop-Top family is an exceptional solution for transporting and serving a variety of menu items and cuisines.

CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plant

Retrieved on: 
Thursday, February 29, 2024

The partnership will leverage Landbell Group’s expertise and network in the sourcing of PET packaging and textile waste which will be prepared for biorecycling.

Key Points: 
  • The partnership will leverage Landbell Group’s expertise and network in the sourcing of PET packaging and textile waste which will be prepared for biorecycling.
  • From 2026, Landbell Group will supply CARBIOS with 15 kt/year of PET flakes, ensuring a steady supply chain for sustainable PET production.
  • These flakes will serve as essential feedstock for CARBIOS’ production of food-grade PTA and MEG, further re-polymerized into PET.
  • The innovative depolymerization process developed by CARBIOS facilitates the recycling of PET waste into high-quality recycled PET.

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Wednesday, February 28, 2024

LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported fourth quarter and full year 2023 financial and operating results.

Key Points: 
  • ET today -
    LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today reported fourth quarter and full year 2023 financial and operating results.
  • Novartis agreed to pay Voyager $80 million of consideration up front and $20 million for the purchase of newly issued equity in Voyager.
  • Collaboration Revenues: Voyager had collaboration revenue of $90.1 million for the fourth quarter of 2023, compared to $(1.6) million for the same period in 2022.
  • ET to discuss the fourth quarter and full year 2023 financial and operating results.

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.

LanzaTech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Outlook

Retrieved on: 
Wednesday, February 28, 2024

CHICAGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming waste carbon into sustainable raw materials, today reported its financial and operating results for the fourth quarter and full year 2023.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    In the fourth quarter of 2023, revenue totaled $20.5 million, reflecting an increase of 77% compared to $11.6 million in the fourth quarter of 2022.
  • Gross margin improved to 41% during the fourth quarter, reflecting certain engineering services work completed during the quarter which benefited from extraordinary pricing terms.
  • “However, our results for the fourth quarter and full year 2023 demonstrate we have a lot more work ahead of us.
  • Cash burn during the fourth quarter 2023 was $(15.4) million, continuing the trend over 2023 of reducing quarterly cash burn.

Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study

Retrieved on: 
Wednesday, February 28, 2024

These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.

Key Points: 
  • These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.
  • GAP is proud that we succeeded in ensuring that the participants in this study reflected the diverse underrepresented populations afflicted with dementia.
  • With the recent approval of disease-modifying Alzheimer’s treatments, there is a growing need to simplify and accelerate an accurate diagnosis.
  • Dr. Richard Mohs observed that “This paper moves the field ahead in simplifying the diagnosis of Alzheimer’s disease.

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.